Flexiseq offers a clinically proven, drug free solution to the pain and stiffness of osteoarthritis. Every tube of Flexiseq is packed with nanoscopic droplets called Sequessome® vesicles which have the optimal characteristics for the lubrication of joint cartilage – size, compressibility and hydration. Working via an entirely physical mode of action, the brand offers a safer alternative to traditional painkillers.
Flexiseq faced a potentially challenging 2022 online, with the typical Flexiseq demographic returning to the high street following the pandemic, and competition within the joint pain remedies category intensifying.
We focused on driving new to brand customers with upper and mid funnel activity, utilising the Amazon advertising stack, targeting new audiences, and positioning Flexiseq within new category and competitor pages.
We improved overall conversion rates, working with best-in-class creative creation for product pages, the brand store and ads, whilst driving and testing multiple ad creatives and copy for different audiences to improve ad conversion rates.
The combination of applied technology, hands-on ad operations and content optimisation has provided Flexiseq with a steady stream of new customers whilst improving the total return on ad spend.
Q1 2023 v Q1 2022
45% increase in revenue
52% increase in page views
41% increase in monthly subscription orders
2022 v 2021
18% increase in revenue
23% increase in monthly subscription orders
10% increase in conversion rate
-24% decrease in average ACOS
15% overall improvement in revenue for every £1 spent